secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001599298-24-000019
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ivonescimab Phase II shows 64.8% 24-month OS in 1L squamous NSCLC; cash ≥$186M
------------------------------------------------------------------------------

- Phase II AK112-201: 24-month OS rate 64.8% in 63 1L squamous NSCLC patients; median OS not reached after 21.0 months follow-up.
- In 19 2L+ EGFRm NSCLC patients (post-TKI), median OS 22.5 months; 12-month OS rate 74%.
- Near-term catalysts: Chinese NDA decision for AK112-301 (Q2 2024) and interim analysis of AK112-303 vs. pembrolizumab (Q2 2024).
- Preliminary cash, cash equivalents, and short-term investments at least $186M as of Dec 31, 2023 (unaudited).
- Two global Phase III trials ongoing: HARMONi (EGFRm NSCLC) and HARMONi-3 (1L squamous NSCLC vs. pembrolizumab).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000019/0001599298-24-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000019/smmt-20240108.htm
  HTML page:      https://secwatch.observer/filing/0001599298-24-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer